Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity

Yi Ban, Junhua Mai, Xin Li, Marisa Mitchell-Flack, Tuo Zhang, Lixing Zhang, Lotfi Chouchane, Mauro Ferrari, Haifa Shen, Xiaojing Ma

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The tumor-promoting potential of CCL5 has been proposed but remains poorly understood. We demonstrate here that an autocrine CCL5-CCR5 axis is a major regulator of immunosuppressive myeloid cells (IMC) of both monocytic and granulocytic lineages. The absence of the autocrine CCL5 abrogated the generation of granulocytic myeloid-derived suppressor cells and tumor-associated macrophages. In parallel, enhanced maturation of intratumoral neutrophils and macrophages occurred in spite of tumor-derived CCL5. The refractory nature of ccl5-null myeloid precursors to tumor-derived CCL5 was attributable to their persistent lack of membrane-bound CCR5. The changes in the ccl5-null myeloid compartment subsequently resulted in increased tumor-infiltrating cytotoxic CD8+ T cells and decreased regulatory T cells in tumor-draining lymph nodes. An analysis of human triple-negative breast cancer specimens demonstrated an inverse correlation between "immune CCR5" levels and the maturation status of tumor-infiltrating neutrophils as well as 5-year-survival rates. Targeting the host CCL5 in bone marrow via nanoparticle-delivered expression silencing, in combination with the CCR5 inhibitor Maraviroc, resulted in strong reductions of IMC and robust antitumor immunities. Our study suggests that the myeloid CCL5-CCR5 axis is an excellent target for cancer immunotherapy.

Original languageEnglish
Pages (from-to)2857-2868
Number of pages12
JournalCancer Research
Volume77
Issue number11
DOIs
Publication statusPublished - 1 Jun 2017

Fingerprint

Myeloid Cells
Immunosuppressive Agents
Immunity
Neoplasms
Neutrophils
Macrophages
Triple Negative Breast Neoplasms
Regulatory T-Lymphocytes
Immunotherapy
Nanoparticles
Lymph Nodes
Bone Marrow
T-Lymphocytes
Membranes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity. / Ban, Yi; Mai, Junhua; Li, Xin; Mitchell-Flack, Marisa; Zhang, Tuo; Zhang, Lixing; Chouchane, Lotfi; Ferrari, Mauro; Shen, Haifa; Ma, Xiaojing.

In: Cancer Research, Vol. 77, No. 11, 01.06.2017, p. 2857-2868.

Research output: Contribution to journalArticle

Ban, Y, Mai, J, Li, X, Mitchell-Flack, M, Zhang, T, Zhang, L, Chouchane, L, Ferrari, M, Shen, H & Ma, X 2017, 'Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity', Cancer Research, vol. 77, no. 11, pp. 2857-2868. https://doi.org/10.1158/0008-5472.CAN-16-2913
Ban, Yi ; Mai, Junhua ; Li, Xin ; Mitchell-Flack, Marisa ; Zhang, Tuo ; Zhang, Lixing ; Chouchane, Lotfi ; Ferrari, Mauro ; Shen, Haifa ; Ma, Xiaojing. / Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity. In: Cancer Research. 2017 ; Vol. 77, No. 11. pp. 2857-2868.
@article{fe385c26ecfb4e2bbedd6e8282fdec7f,
title = "Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity",
abstract = "The tumor-promoting potential of CCL5 has been proposed but remains poorly understood. We demonstrate here that an autocrine CCL5-CCR5 axis is a major regulator of immunosuppressive myeloid cells (IMC) of both monocytic and granulocytic lineages. The absence of the autocrine CCL5 abrogated the generation of granulocytic myeloid-derived suppressor cells and tumor-associated macrophages. In parallel, enhanced maturation of intratumoral neutrophils and macrophages occurred in spite of tumor-derived CCL5. The refractory nature of ccl5-null myeloid precursors to tumor-derived CCL5 was attributable to their persistent lack of membrane-bound CCR5. The changes in the ccl5-null myeloid compartment subsequently resulted in increased tumor-infiltrating cytotoxic CD8+ T cells and decreased regulatory T cells in tumor-draining lymph nodes. An analysis of human triple-negative breast cancer specimens demonstrated an inverse correlation between {"}immune CCR5{"} levels and the maturation status of tumor-infiltrating neutrophils as well as 5-year-survival rates. Targeting the host CCL5 in bone marrow via nanoparticle-delivered expression silencing, in combination with the CCR5 inhibitor Maraviroc, resulted in strong reductions of IMC and robust antitumor immunities. Our study suggests that the myeloid CCL5-CCR5 axis is an excellent target for cancer immunotherapy.",
author = "Yi Ban and Junhua Mai and Xin Li and Marisa Mitchell-Flack and Tuo Zhang and Lixing Zhang and Lotfi Chouchane and Mauro Ferrari and Haifa Shen and Xiaojing Ma",
year = "2017",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-16-2913",
language = "English",
volume = "77",
pages = "2857--2868",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity

AU - Ban, Yi

AU - Mai, Junhua

AU - Li, Xin

AU - Mitchell-Flack, Marisa

AU - Zhang, Tuo

AU - Zhang, Lixing

AU - Chouchane, Lotfi

AU - Ferrari, Mauro

AU - Shen, Haifa

AU - Ma, Xiaojing

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The tumor-promoting potential of CCL5 has been proposed but remains poorly understood. We demonstrate here that an autocrine CCL5-CCR5 axis is a major regulator of immunosuppressive myeloid cells (IMC) of both monocytic and granulocytic lineages. The absence of the autocrine CCL5 abrogated the generation of granulocytic myeloid-derived suppressor cells and tumor-associated macrophages. In parallel, enhanced maturation of intratumoral neutrophils and macrophages occurred in spite of tumor-derived CCL5. The refractory nature of ccl5-null myeloid precursors to tumor-derived CCL5 was attributable to their persistent lack of membrane-bound CCR5. The changes in the ccl5-null myeloid compartment subsequently resulted in increased tumor-infiltrating cytotoxic CD8+ T cells and decreased regulatory T cells in tumor-draining lymph nodes. An analysis of human triple-negative breast cancer specimens demonstrated an inverse correlation between "immune CCR5" levels and the maturation status of tumor-infiltrating neutrophils as well as 5-year-survival rates. Targeting the host CCL5 in bone marrow via nanoparticle-delivered expression silencing, in combination with the CCR5 inhibitor Maraviroc, resulted in strong reductions of IMC and robust antitumor immunities. Our study suggests that the myeloid CCL5-CCR5 axis is an excellent target for cancer immunotherapy.

AB - The tumor-promoting potential of CCL5 has been proposed but remains poorly understood. We demonstrate here that an autocrine CCL5-CCR5 axis is a major regulator of immunosuppressive myeloid cells (IMC) of both monocytic and granulocytic lineages. The absence of the autocrine CCL5 abrogated the generation of granulocytic myeloid-derived suppressor cells and tumor-associated macrophages. In parallel, enhanced maturation of intratumoral neutrophils and macrophages occurred in spite of tumor-derived CCL5. The refractory nature of ccl5-null myeloid precursors to tumor-derived CCL5 was attributable to their persistent lack of membrane-bound CCR5. The changes in the ccl5-null myeloid compartment subsequently resulted in increased tumor-infiltrating cytotoxic CD8+ T cells and decreased regulatory T cells in tumor-draining lymph nodes. An analysis of human triple-negative breast cancer specimens demonstrated an inverse correlation between "immune CCR5" levels and the maturation status of tumor-infiltrating neutrophils as well as 5-year-survival rates. Targeting the host CCL5 in bone marrow via nanoparticle-delivered expression silencing, in combination with the CCR5 inhibitor Maraviroc, resulted in strong reductions of IMC and robust antitumor immunities. Our study suggests that the myeloid CCL5-CCR5 axis is an excellent target for cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85020822263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020822263&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-2913

DO - 10.1158/0008-5472.CAN-16-2913

M3 - Article

C2 - 28416485

AN - SCOPUS:85020822263

VL - 77

SP - 2857

EP - 2868

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 11

ER -